Product description

NanaBis™ is a pharmaceutical grade formulation that consists of a racemic mixture of Delta–9–Tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1 to 1 ratio. The formulation is a highly purified, standardised 1:1 blend CBD and THC in a patented submicron particle delivery platform optimized for buccal delivery. 

CLINICAL TRIAL:
The buccal administration of a Cannabis sativa L./Cannabis indica L. extract as an adjunct to opioid analgesia for the management of intractable pain in patients diagnosed with advanced cancer: a safety, tolerability and exploratory end-point pilot study

HREC approval: 16 June 2017
HREC: Northern Sydney Local Health District
HREC Approval ID: HREC/16/HAWKE/496
CTN: CT-2017-CTN-02369-1 v3
ANZCTR: ACTRN12617001480370
STUDY SITE: Royal North Shore Hospital, Oncology Department
STATUS: Completed


IP RIGHTS:

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: CanadaApplication number: 2978179Filing Date: 2nd March 16 Status: Filed

Patent Title: Transmucosal and transdermal delivery systems// NanoCelle.Jurisdiction: EuropeApplication number: 16759418.3Filing Date: 2nd March 16 Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelle.Jurisdiction: New ZealandApplication number: 735138Filing Date:  2nd March 2016 Status: Examination Requested
Patent Title: Transmucosal and transdermal delivery systems// NanoCelle.Jurisdiction: SingaporeApplication number: 11201707068XFiling Date: 2nd March 2016 Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelle.Jurisdiction: United StatesApplication number: 15/555038 Filing Date: 2nd March 2016Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelle.Jurisdiction: Hong KongApplication number: 18103321.4Filing Date: 2nd March 2016Status: Filed
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: AustraliaApplication number: 2017261847Filing Date: 11 May 2016Status: Accepted
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: CanadaApplication number: 3023767Filing Date: 11 May 2016Status: Filed 
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: EuropeApplication number: 17795190.2Filing Date: 11 May 2016Status: under examination 
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: New Zealand Application number: 748609Filing Date: 11 May 2016Status:examination requested
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: SingaporeApplication number: 11201809976P Filing Date: 11 May 2016Status: Under examination
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: United StatesApplication number: 16/300537Filing Date: 11 May 2016Status: Under examination
Patent Title: Protection of plant extracts and compounds from degradation API Degradation. Jurisdiction: Hong KongApplication number: 19122060.7Filing Date: 11 May 2016Status: Filed

Read more

Specifications

Categories Pharmaceutical Machinery & TechnologyBioavailability enhancement; Pharmaceutical PackagingDrug Delivery Systems; Finished Dosage Forms
Sales markets Western Europe; Eastern Europe; Middle East; Australia; North America; Central/South America
Supplied from Australia

More products from Medlab Clinical LTD

View all our products (10)

Products from other suppliers